Some corporate venture funds back biotechs for a strategic position, and others to feed the innovation ecosystem. Either way, the money flow from these big pharma divisions has followed that of investment in general over the past few years – namely, into oncology research.
That said, the corporate VCs have taken their feet off the oncology accelerator, an analysis by Vantage shows. Making a surprising surge since 2015 is corporate VC interest in companies working on central nervous system projects, perhaps reflecting the risky nature of drug development in this area and the need for patient investment.
